Comparing Glycopyrronium/Formoterol Combination Therapy With Monotherapy in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD): A Narrative Review

被引:0
作者
Prada, Bollineni S. [1 ]
Jadhav, Ulhas [1 ]
Ghewade, Babaji [1 ]
Wagh, Pankaj [1 ]
Karnan, Ashwin [1 ]
Ledwani, Anjana [1 ]
机构
[1] Datta Meghe Inst Higher Educ & Res, Jawaharlal Nehru Med Coll, Resp Med, Wardha, India
关键词
safety; efficacy; formoterol; glycopyrronium; combination therapy; copd; FIXED-DOSE COMBINATION; CARDIOVASCULAR SAFETY; PALLIATIVE CARE; GLYCOPYRROLATE; EFFICACY;
D O I
10.7759/cureus.58633
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic obstructive pulmonary disease (COPD) imposes a significant burden on individuals and healthcare systems globally. While bronchodilators, such as glycopyrronium and formoterol, are cornerstone therapies for COPD management, combining these agents has gained attention for potentially improving outcomes compared to monotherapy. This comprehensive review aims to assess the efficacy and safety of glycopyrronium/formoterol (GFF) combination therapy versus glycopyrronium monotherapy in patients with moderate-to-severe COPD. Through a systematic evaluation of clinical trials and real-world evidence, we analyze the impact of combination therapy on lung function, symptom control, exacerbation rates, and health-related quality of life (HRQoL). Furthermore, we examine the safety profile of combination therapy, including adverse cardiovascular and respiratory events. Comparative analyses with glycopyrronium monotherapy provide insights into the relative benefits and considerations for treatment selection. Factors influencing treatment choice and future directions in COPD management are also discussed. This review underscores the potential of combination therapy in optimizing COPD treatment outcomes and highlights areas for further research and clinical practice refinement.
引用
收藏
页数:10
相关论文
共 50 条
[21]   Correlates of erectile dysfunction in moderate-to-severe chronic obstructive pulmonary disease patients [J].
Karadag, Fisun ;
Ozcan, Hatice ;
Karul, Aslihan B. ;
Ceylan, Emel ;
Cildag, Orhan .
RESPIROLOGY, 2007, 12 (02) :248-253
[22]   Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study [J].
Wang, Chen ;
Sun, Tieying ;
Huang, Yijiang ;
Humphries, Michael ;
Bai, Lingyan ;
Li, Lilly ;
Wang, Qian ;
Kho, Pearl ;
Firth, Roz ;
D'Andrea, Peter .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 :57-68
[23]   Self-management support for moderate-to-severe chronic obstructive pulmonary disease: a pilot randomised controlled trial [J].
Taylor, Stephanie J. C. ;
Sohanpal, Ratna ;
Bremner, Stephen A. ;
Devine, Angela ;
McDaid, David ;
Fernandez, Jose-Luis ;
Griffiths, Chris J. ;
Eldridge, Sandra .
BRITISH JOURNAL OF GENERAL PRACTICE, 2012, 62 (603) :e687-e695
[24]   QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease [J].
Frampton, James E. .
DRUGS, 2014, 74 (04) :465-488
[25]   Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review [J].
Ulrik, Charlotte Suppli .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2014, 9 :331-338
[26]   Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma [J].
Corren, Jonathan ;
Mansfield, Lyndon E. ;
Pertseva, Tetyana ;
Blahzko, Viktor ;
Kaiser, Kirsten .
RESPIRATORY MEDICINE, 2013, 107 (02) :180-195
[27]   Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD [J].
Salvi, Sundeep ;
Kumar, Anand ;
Agrawal, Sumit ;
Leuva, Amrutlal ;
Shukla, Vineet ;
Deshpande, Shrikant ;
Balamurugan, Santhalingum ;
Singh, Ajeet ;
Tikkiwal, Sharad ;
Gupta, Sandeep ;
Sawant, Sandesh ;
Vaidya, Abhijit ;
Gogtay, Jaideep .
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[28]   Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate compared with dual therapy for the treatment of chronic obstructive pulmonary disease (COPD) in Canada [J].
Johnston, Karissa ;
Shephard, Cal ;
Friesen, Michael ;
Azzalini, Caitlin ;
Penz, Erika .
CANADIAN JOURNAL OF RESPIRATORY CRITICAL CARE AND SLEEP MEDICINE, 2024, 8 (01) :4-16
[29]   Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review [J].
Melani, Andrea S. .
EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (14) :1603-1611
[30]   Budesonide and formoterol combination for the treatment of chronic obstructive pulmonary disease [J].
Centanni, S ;
Di Marco, F .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (14) :2525-2534